New data revealing a link between the LDL receptor-related protein 4 (LRP4) and amyotrophic lateral sclerosis (ALS) was presented during the 67th American Academy of Neurology Annual Meeting in April 2015. The presentation was entitled “LRP4 antibodies are frequent in serum and CSF from amyotrophic lateral sclerosis patients”. ALS is…

In a recent study published in the journal eLife, a team of researchers at Stanford University was able to identify a group of neurons that work together and fire in complex rhythms to send movement signals to muscles. “We hope to apply these findings to create prosthetic…

Researchers at Columbia University, New York recently published in the journal Cell Reports their findings on eight different master regulators involved in amyotrophic lateral sclerosis (ALS) neurodegeneration in mouse models. The study is entitled “The Regulatory Machinery of Neurodegeneration in In Vitro Models…

The ALS Association together with the ALS Finding a Cure Foundation recently announced a $3 million funding for two Phase II clinical trials via the ALS Accelerated Therapeutics (ALS ACT) initiative, a project focused on accelerating the discovery of new ALS therapies in part by funding pilot clinical…

The ALS Association has recently awarded a $1.5 million grant to investigator Robert G. Miller, MD, to be invested in the study of a potential treatment for amyotrophic lateral sclerosis (ALS), called NP001. Dr. Miller is studying Neuraltus Pharmaceuticals’ investigational therapy which will now enter a phase 2 clinical trial.

Genervon Biopharmaceuticals recently announced it has filed a patent application based on data from the Phase 2A clinical trial (GALS001 study, NCT01854294) assessing the company’s product GM604 as a therapy for amyotrophic lateral sclerosis (ALS) and data from a single ALS compassionate patient study (GALS-C). ALS is a…

Chris Rosati, who was diagnosed with amyotrophic lateral sclerosis (ALS) in November 2010, challenged the ALS Association to publicly declare that a cure for the disease will be found in the next six years. In an emotional video addressed to the association’s CEO Barbara Newhouse, Mr. Rosati explained…

The ALS Association participated in the annual BIO International Convention, which occured between June 15 and 18 in Philadelphia. Over 15,000 leaders from the pharmaceutical and biotech industries joined the convention which provided the association with crucial opportunities to establish partnerships that may further the development of treatments for amyotrophic lateral sclerosis disease (ALS). ALS is a…

The ALS (amyotrophic lateral sclerosis) Association revealed that a team of researchers funded by the Association and led by Dr. Timothy Miller and Dr. Randall Bateman from Washington University in Saint Louis, recently discovered important insights into the ALS-related protein called copper (Cu)/zinc (Zn) superoxide dismutase (SOD1). ALS…

Researchers at CRCHUM and the University of Montreal in Canada discovered a previously unknown link between amyotrophic lateral sclerosis (ALS) neurodegeneration and the immune system. The study was recently published in the journal Nature Communications and is entitled “Neurodegeneration in C. elegans models…